Skip to main content
. 2020 Jan 10;2020:6786302. doi: 10.1155/2020/6786302

Table 1.

Baseline characteristics of study population.

Control (n = 48) CAD (n = 248) P value
Age (years) 61.15 ± 8.02 61.54 ± 8.36 0.705
Sex (n, male) 23 (47.9%) 105 (42.3%) 0.475
Hypertension (n, %) 0 (0%) 126 (73.3%) NS
Diabetes mellitus (n, %) 0 (0%) 53 (30.8%) NS
Smoking (n, %) 0 (0%) 89 (51.7%) NS
HbA1c (%) 5.97 ± 0.68 6.35 ± 1.21 0.009∗∗
CK-MB (U/L) 9.2 (7.7, 11.4) 11.0 (9.0, 13.4) 0.003∗∗
TnI 0.003 (0.001, 0.008) 0.007 (0.003, 0.023) <0.001∗∗
TC 4.73 (3.98, 5.38) 4.69 (4.09, 5.48) 0.860
TG 1.21 (1.00, 1.67) 1.51 (1.16, 2.04) 0.011
HDL-c 1.35 (1.13, 1.60) 1.17 (1.02, 1.35) 0.002∗∗
LDL-c (mg/dL) 3.05 ± 0.63 2.88 ± 0.68 0.086
Cr (mg/dL) 70.06 ± 5.75 71.95 ± 9.27 0.066
LVEF (%) 60.33 ± 3.61 59.14 ± 5.42 0.145
Gensini score NS 38 (17, 74) NS
PCI (n, %) NS 100 (40.3%) NS
VEGF (pg/mL) 160.93 (121.09, 303.26) 645.57 (319.48, 901.14) <0.001∗∗

Date are expressed as mean ± SD (standard deviation), median (interquartile range), and absolute number (percentage). P value for comparison between the CAD and the control group. ∗∗P < 0.01. HbA1c: hemoglobin A1c; CK-MB: creatine kinase-MB; TnI: troponin I; TC: total cholesterol; TG: triglyceride; HDL-c: high-density lipoprotein cholesterol; LDL-c: low-density lipoprotein cholesterol; Cr = creatinine; LVEF: left ventricular ejection fraction; PCI: percutaneous coronary intervention; VEGF = vascular endothelial growth factor.